These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 8306321)
1. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. McKeage MJ; Boxall FE; Jones M; Harrap KR Cancer Res; 1994 Feb; 54(3):629-31. PubMed ID: 8306321 [TBL] [Abstract][Full Text] [Related]
2. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Hamers FP; Brakkee JH; Cavalletti E; Tedeschi M; Marmonti L; Pezzoni G; Neijt JP; Gispen WH Cancer Res; 1993 Feb; 53(3):544-9. PubMed ID: 8425186 [TBL] [Abstract][Full Text] [Related]
3. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Screnci D; McKeage MJ; Galettis P; Hambley TW; Palmer BD; Baguley BC Br J Cancer; 2000 Feb; 82(4):966-72. PubMed ID: 10732773 [TBL] [Abstract][Full Text] [Related]
4. The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum. Cerri S; Piccolini VM; Santin G; Bottone MG; De Pascali SA; Migoni D; Iadarola P; Fanizzi FP; Bernocchi G Neurotoxicol Teratol; 2011; 33(2):273-81. PubMed ID: 20883777 [TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
6. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935 [TBL] [Abstract][Full Text] [Related]
7. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes. Kim WK; Kwon YE Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue. Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402 [TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332 [TBL] [Abstract][Full Text] [Related]
10. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Holmes J; Stanko J; Varchenko M; Ding H; Madden VJ; Bagnell CR; Wyrick SD; Chaney SG Toxicol Sci; 1998 Dec; 46(2):342-51. PubMed ID: 10048138 [TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Jamieson SM; Liu J; Connor B; McKeage MJ Cancer Chemother Pharmacol; 2005 Oct; 56(4):391-9. PubMed ID: 15887017 [TBL] [Abstract][Full Text] [Related]
12. Alterations in cell cycle regulation underlie cisplatin induced apoptosis of dorsal root ganglion neurons in vivo. Fischer SJ; McDonald ES; Gross L; Windebank AJ Neurobiol Dis; 2001 Dec; 8(6):1027-35. PubMed ID: 11741398 [TBL] [Abstract][Full Text] [Related]
13. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Cavaletti G; Petruccioli MG; Marmiroli P; Rigolio R; Galbiati S; Zoia C; Ferrarese C; Tagliabue E; Dolci C; Bayssas M; Griffon Etienne G; Tredici G Anticancer Res; 2002; 22(6C):4199-204. PubMed ID: 12553056 [TBL] [Abstract][Full Text] [Related]
14. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. McKeage MJ; Hsu T; Screnci D; Haddad G; Baguley BC Br J Cancer; 2001 Oct; 85(8):1219-25. PubMed ID: 11710838 [TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat. Smith JH; Smith MA; Litterst CL; Copley MP; Uozumi J; Boyd MR Fundam Appl Toxicol; 1988 Jan; 10(1):45-61. PubMed ID: 3350229 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. McDonald ES; Randon KR; Knight A; Windebank AJ Neurobiol Dis; 2005 Mar; 18(2):305-13. PubMed ID: 15686959 [TBL] [Abstract][Full Text] [Related]
19. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat. Smith MA; Smith JH; Litterst CL; Copley MP; Uozumi J; Boyd MR Fundam Appl Toxicol; 1988 Jan; 10(1):62-72. PubMed ID: 3350230 [TBL] [Abstract][Full Text] [Related]
20. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]